Literature DB >> 24296493

Evaluation of GeneXpert MTB/RIF for the detection of Mycobacterium tuberculosis and resistance to rifampin in clinical specimens.

Eleonora Bunsow1, María Jesús Ruiz-Serrano2, Paula López Roa3, Martha Kestler3, Dario Garcia Viedma2, Emilio Bouza4.   

Abstract

OBJECTIVES: GeneXpert (GX) is a novel real-time polymerase chain reaction assay for the simultaneous detection of Mycobacterium tuberculosis (MTB) and resistance to rifampin (RIF). We evaluated the performance of GX for direct detection of MTB in respiratory and non-respiratory specimens and assessed the ability of the assay to detect resistance to RIF in non-tuberculosis (TB) endemic country.
METHODS: We analyzed 595 clinical samples in a 1550-bed tertiary hospital in Madrid, Spain. Specimens were processed using GX, auramine smear, conventional culture, and drug phenotypic susceptibility testing (DST) with MGIT SIRE (BD).
RESULTS: Of the 595 clinical samples, 305 (51.3%) were non-respiratory and 290 (48.7%) were respiratory. In total, MTB was isolated in 81 specimens, 71 of which were positive with GX. The sensitivity, specificity, PPV, and NPV of the GX were: 97.1%, 98.6%, 95.7% and 99.1% for respiratory samples and 33.3%, 99.7%, 80.0% and 97.3% for non-respiratory. GX detected 8 RIF-resistant samples, but only 5 were confirmed by DST.
CONCLUSIONS: GX is an accurate, easy-to-apply and rapid test to detect MTB, especially in smear-positive respiratory samples. Although is a useful tool for the rapid identification of RIF-resistant MTB strains, the rifampin resistant results should be confirmed by DST.
Copyright © 2013 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  GeneXpert; Molecular diagnosis; Rifampin-resistant; Tuberculosis

Mesh:

Substances:

Year:  2013        PMID: 24296493     DOI: 10.1016/j.jinf.2013.11.012

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  19 in total

1.  Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV-1 infection 2015: optimizing health in preparation for adult life.

Authors:  A Bamford; A Turkova; H Lyall; C Foster; N Klein; D Bastiaans; D Burger; S Bernadi; K Butler; E Chiappini; P Clayden; M Della Negra; V Giacomet; C Giaquinto; D Gibb; L Galli; M Hainaut; M Koros; L Marques; E Nastouli; T Niehues; A Noguera-Julian; P Rojo; C Rudin; H J Scherpbier; G Tudor-Williams; S B Welch
Journal:  HIV Med       Date:  2015-02-03       Impact factor: 3.180

2.  Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Mandy Yao; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2021-01-15

Review 3.  Evaluation of the Cepheid Xpert MTB/RIF assay.

Authors:  Thomas M Shinnick; Angela M Starks; Heather L Alexander; Kenneth G Castro
Journal:  Expert Rev Mol Diagn       Date:  2014-11-06       Impact factor: 5.225

4.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

Review 5.  Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.

Authors:  Mikashmi Kohli; Ian Schiller; Nandini Dendukuri; Keertan Dheda; Claudia M Denkinger; Samuel G Schumacher; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2018-08-27

6.  Multicenter Evaluation of Anyplex Plus MTB/NTM MDR-TB Assay for Rapid Detection of Mycobacterium tuberculosis Complex and Multidrug-Resistant Isolates in Pulmonary and Extrapulmonary Specimens.

Authors:  Michela Sali; Flavio De Maio; Francesca Caccuri; Federica Campilongo; Maurizio Sanguinetti; Simona Fiorentini; Giovanni Delogu; Cinzia Giagulli
Journal:  J Clin Microbiol       Date:  2015-10-21       Impact factor: 5.948

Review 7.  Clinical application of QuantiFERON-TB Gold in-tube in the diagnosis and treatment of tuberculosis.

Authors:  Guangming Chen; Huabin Wang; Yanhong Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-11-30       Impact factor: 3.267

8.  Improved diagnostic sensitivity for tuberculous meningitis with Xpert(®) MTB/RIF of centrifuged CSF.

Authors:  N C Bahr; L Tugume; R Rajasingham; R Kiggundu; D A Williams; B Morawski; D Alland; D B Meya; J Rhein; D R Boulware
Journal:  Int J Tuberc Lung Dis       Date:  2015-10       Impact factor: 2.373

9.  A comparison between the efficiency of the Xpert MTB/RIF assay and nested PCR in identifying Mycobacterium tuberculosis during routine clinical practice.

Authors:  Cheol-Hong Kim; Heungjeong Woo; In Gyu Hyun; Changhwan Kim; Jeong-Hee Choi; Seung-Hun Jang; Sang Myeon Park; Dong-Gyu Kim; Myung Goo Lee; Ki-Suck Jung; Jeongwon Hyun; Hyun Soo Kim
Journal:  J Thorac Dis       Date:  2014-06       Impact factor: 2.895

10.  Fluctuating Behavior and Influential Factors in the Performance of the QuantiFERON-TB Gold In-Tube Assay in the Diagnosis of Tuberculosis.

Authors:  Lei Bao; Tao Li; Ni Diao; Yaojie Shen; Lingyun Shao; Ying Zhang; Shuihua Lu; Wenhong Zhang
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.